Enbrel Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The enbrel market research report is one of a series of new reports that provides enbrel market statistics, including enbrel industry global market size, regional shares, competitors with a enbrel market share, detailed enbrel market segments, market trends and opportunities, and any further data you may need to thrive in the enbrel industry. This enbrel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The enbrel market size is expected to see strong growth in the next few years. It will grow to $20,930.9 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to growing use of enbrel in multiple indications, increasing government support for biologics and rheumatoid arthritis (ra) treatment, growing awareness of autoimmune diseases, rising awareness of inflammatory diseases in the general population, increasing availability of biosimilars, promoting awareness of enbrel. Major trends in the forecast period include digital healthcare tools for managing autoimmune diseases, global partnerships between pharmaceutical companies, development of long-acting injectable formulations for better patient compliance, integration of artificial intelligence in drug development for autoimmune diseases, development of alternative delivery systems for biologic drugs.

The growing prevalence of autoimmune conditions is anticipated to fuel the expansion of the Enbrel market. Autoimmune conditions arise when the immune system erroneously attacks the body’s healthy cells and tissues, causing inflammation and damage to various organs. This increasing prevalence is linked to factors such as genetic predisposition, environmental triggers, and lifestyle or immune system behavior changes. The rising number of autoimmune cases boosts the demand for treatments like Enbrel, which manages inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. For example, in August 2022, the National Library of Medicine reported approximately 928 cases of autoimmune conditions associated with COVID-19 vaccination in 2022. Among these, 81.5% (756 cases) were new-onset autoimmune diseases, with symptoms typically appearing eight days post-vaccination. Women accounted for 53.6% of the cases, with a median age of 48. Thus, the growing prevalence of autoimmune conditions is projected to drive the Enbrel market forward.

A significant trend in the Enbrel market involves obtaining regulatory drug approvals to enhance competitive positioning. Drug approval processes involve regulatory authorities assessing and authorizing new drugs for safety, efficacy, and quality based on clinical trial data. For instance, in October 2023, Amgen Inc., a US-based biopharmaceutical company, announced FDA approval for Enbrel to treat children aged two and older with active juvenile psoriatic arthritis (JPsA). This approval underscores the unique attributes of etanercept as a tumor necrosis factor blocker, demonstrated through comprehensive safety and efficacy studies in adults with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and psoriasis. It also includes pharmacokinetic (PK) data supporting its use in pediatric patients with active juvenile idiopathic arthritis (JIA) and psoriasis. The recommended dosage for juvenile PsA (JPsA) is weight-based and administered via weekly subcutaneous injection.

In November 2023, Amazon Web Services Inc. (AWS), a US-based cloud computing company, partnered with Amgen Inc. to enhance production output and expedite global delivery of medications to patients. Through this collaboration, Amgen is utilizing AWS to develop generative AI-based solutions to accelerate the discovery, development, and manufacturing processes for medicines aimed at treating serious illnesses. Amgen Inc. is a US-based producer of Enbrel.

The key copanies operating in the enbrel market is Amgen Inc.

North America was the largest region in the enbrel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enbrel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the enbrel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Enbrel (generic name: etanercept) is a prescription drug used to manage various autoimmune disorders by suppressing the immune system. This biologic medication functions by blocking tumor necrosis factor (TNF), a substance that contributes to inflammation in conditions like rheumatoid arthritis and psoriasis.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Enbrel is available in several forms, including injectable solutions, prefilled syringes, combination therapies, extended-release formulations, and biosimilars. Injectable solutions are liquid medications administered via injection. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and other related conditions.

The enbrel market consists of sales of monoclonal antibodies, cancer immunotherapy drugs and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.